300110 华仁药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.349-43.289-68.5127.1997.375
总资产报酬率 ROA (%)1.047-15.102-31.8483.6423.346
投入资产回报率 ROIC (%)1.308-18.134-35.8444.0263.818

边际利润分析
销售毛利率 (%)32.62637.04535.20242.72343.272
营业利润率 (%)6.569-34.484-99.98713.80912.256
息税前利润/营业总收入 (%)9.619-31.529-96.13817.95916.754
净利润/营业总收入 (%)5.026-34.764-100.71511.82111.195

收益指标分析
经营活动净收益/利润总额(%)112.316-25.492-6.118100.402108.010
价值变动净收益/利润总额(%)0.969-1.0490.0860.366-0.673
营业外收支净额/利润总额(%)-2.0670.7070.2041.9833.579

偿债能力分析
流动比率 (X)0.8010.6740.7661.8411.345
速动比率 (X)0.6240.5100.5601.6201.214
资产负债率 (%)65.83266.35659.92246.45549.645
带息债务/全部投入资本 (%)58.73258.73454.55641.40041.876
股东权益/带息债务 (%)66.55466.43880.605139.113129.542
股东权益/负债合计 (%)47.86646.73263.324112.26698.742
利息保障倍数 (X)3.022-9.850-23.7174.6394.144

营运能力分析
应收账款周转天数 (天)139.836137.650157.117142.065160.014
存货周转天数 (天)106.306121.111134.024115.520106.255